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INTRODUCTION
Cervical cancer is the second type of cancer in
women in the world and most cancers occur in
women in developing countries. Lymph node
metastasis in pelvic, size of tumor, depth invasion
of the stroma, the invasion of parametrial and
emboli limfo vascular will affect the recurrence
and distant metastasis as well as a prognostic
factor in early stage cervical cancer.1,2
Radical hysterectomy with pelvic lymphadenec-
tomy was performed for cervical cancer stage IB
and IIA. 5-years cure rate in patients without
lymph node metastasis is 70-90% and is decreased
to 40-60% in patients with lymph node metastasis.
There was a reported in early-stage cervical cancer
patients who undergo radical histerectomy and
bilateral pelvic lymphadenectomy is detected as
many as 83% of the total invasion limfo vascular,
77% are stage IB and from that stage, there are
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Objective: To determine the relationship of Vascular Endothelial
Growth Factors-C (VEGF-C), endostatin and the ratio of VEGF-C/
endostatin with limfo vascular invasion in patient with early stage
cervical cancer.
Methods: This study used a cross sectional method. Samples were
all patients with early stage cervical cancer who came to the several
teaching hospitals of Obstetrics and Gynecology Department
Universitas Hasanuddin Medical Faculty that meet the criteria,
then we measured the levels of VEGF-C and endostatin.
Results: We get 30 women with cervical carcinoma. The results
showed that the serum levels of VEGF-C was higher in limfo vascular
invasion positive (p = 0.017); the ratio of VEGF-C/ endostatin higher
in limfo vascular invasion positive (p = 0.004); whereas serum levels
of endostatin did not differ significantly in limfo vascular invasion
positive or negative (p = 0.522).
Conclusion: The level of VEGF-C and VEGF-C/ endostatin ratio
was higher in patients with early stage cervical cancer with
positive LVSI than negative LVSI.
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Abstrak
Tujuan: Untuk mengetahui hubungan Vaskular Endothelial
Growth Factors-C (VEGF-C) dan Endostatin serta rasio VEGF-C/endostatin dengan invasi limfo vaskuler pada pasien kanker
serviks uteri stadium awal.
Metode: Penelitian ini menggunakan metode cross sectional. Sampel
penelitian adalah semua penderita kanker serviks uteri stadium awal
yang datang ke Bagian Obstetrik dan Ginekologi Rumah Sakit UmumPendidikan Universitas Hasanuddin dan jejaringnya yang memenuhi
kriteria inklus yang kemudian dilakukan pengukuran kadar VEGF-Cdan Endostatin.
Hasil: Kami mendapatkan 30 perempuan penderita karsinomaserviks. Hasil penelitian menunjukkan bahwa kadar serum VEGF-C
lebih tinggi pada invasi limfo-vaskuler positif (p = 0,017); rasio
VEGF-C/ Endostatin lebih tinggi pada invasi limfo-vaskuler positif(p = 0,004); sedangkan kadar serum endostatin tidak berbeda
secara bermakna pada invasi limfo-vaskuler positif ataupun negatif(p = 0,522).
Kesimpulan: Kadar VEGF-C dan rasio VEGF-C/Endostatin lebih tinggipada pasien kanker serviks uteri stadium awal dengan LVSI positif
dibandingkan dengan LVSI negatif.
[Maj Obstet Ginekol Indones 2017; 5-2: 105-109]
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21% got lymph node metastasis. Women with
positive pelvic lymph nodes have recurrence risk
and should be treated aggressively.1,3
Tumor growth, neovascularization and metas-
tasis depend on the ability of cancer cells to
invade the tissue that consist extracellular matrix
degradation and basal membrane structure. Tumor
invasion and metastasis are also crucial step in
determining the aggressiveness of the cancer and
the cause of death due to cancer. Molecular under-
standing that leads to metastasis as well as the
complex interaction between the host cell metas-
tasis, important in deciding more effective cancer
therapy. Family Vascular endothelial growth factor
(VEGF) VEGF-A, B, C, D, E is particularly important
because it causes angiogenesis and limfangioge-
nesis which will further lead to tumor growth and
metastasis of cancer.4-6
Several studies have been carried out by com-
paring the VEGF with endostatin in several human
cancers, Shaarawy et al (2001) conducted a study
of postmenopausal women: 72 endometrial
cancers, 27 endometrial hyperplasia and 30
healthy female controls and compare their levels
of VEGF and endostatin at each in each case. It was
found that the serum levels of VEGF in endometrial
hyperplasia (142  18 ng/ml) and endometrial
cancer stage I (291  22 ng/ml), II (623  68
ng/ml) and stage III- IV (1527  119 ng/ml) was
significantly higher than the average of the controls
(12  1.6 ng/ml). Serum levels of endostatin on
endometrial hyperplasia (149  19 ng/ml), endo-
metrial cancer stage I (320  41 ng/ml), II (644 
86 ng/ml) and stage III-IV (1253  114 ng/ml) also
significantly higher than the average of the controls
(13  2.4 ng/ml). Elevated VEGF values above the
normal levels achieved in nonmalignant state by
7% (stage I), 37% (stage II) and 100% (stage III-
IV) of endometrial cancer. While endostatin was
respectively 37%, 59% and 100%.7-9
These results suggested that both of the bio-
marker levels in the circulation were associated
with staging of the tumor. Serum levels of VEGF
and endostatin were significantly decreased after
treatment, but will rise again if there is a relapse.
The ratio of VEGF - endostatin was higher in
advanced stage compared with early stage endo-
metrial cancer. This shows that the balance
between angiogenic stimulators with angiogenic
inhibitor can affect metastasis and tumor pro-
gression.7,10
The objective of this study is to determine the
relationship of VEGF-C, endostatin, ratio VEGF- C/
endostatin with limfo vascular invasion in patients
with early-stage cervical cancer.
METHODS
The study method was cross sectional. This study
was conducted in several teaching hospitals
of Obstetrics and Gynecology department
Universitas Hasanuddin Faculty of Medicine in
Makassar from February 2014 until February
2015. The population were women with early
stage of cervical uteri cancer who examined in
several teaching hospitals of Obstetrics and
Gynecology department Universitas Hasanuddin
Medical Faculty in Makassar. Samples who met
the criteria and approved the informed consent.
Data processing with SPSS. Data analysis use T
independent test and Mann Whitney test.
Hypothesis testing determined significant if
<0.05.
RESULTS
There were 30 samples who met inclusion criteria.
In this study, the results of distribution charac-
teristics shown in Table 1.
Table 1. Characteristics Comparison Distribution of the
Study Sample
Characteristic Sample(n=30)
Percentage
(%=100)
Age
< 45 years old 13 43.33
45-55 years old 14 46.67
> 55 years old 3 10.00
Education
Elementary school 7 23.33
Middle school 11 36.67
High school 10 33.33
University 2 6.67
Occupation
Housewife 28 93.33
Enterpreneur 2 6.67
Age when first married
 16 years old 27 90
< 16 years old 3 10
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Table 2 shows the characteristics of biological
distribution and we obtained sample highest LVSI
positives and negatives in stage IB 2 each 6 cases
(40%), from that sample the most histopathologic
type are invasive squamous cell carcinoma 12
cases (80%) and 7 cases (46.67%), respectively.
Middle differentiation was the most in LVSI posi-
tive or negative.
Table 3 demonstrates the comparison level of
VEGF-C, endostatin and ratio VEGF-C/ endostatin.
VEGF-C Serum higher in LVSI positive with mean
12720.40  2593.13 that LVSI negative. Serum
levels of endostatin higher in LVSI positive with
mean value 178.20  33.99, and ratio VEGF-C/
endostatin higher in LVSI positive that LVSI
negative with a mean value 71.39  6.16 and
P = 0.04.
Characteristic Sample(n=30)
Percentage
(%=100)
Parity
Primipara 2 6.67
Multipara 28 93.33
Frequence of married
Once 28 93.33
Twice 2 6.67
Contraception use
DMPA 7 23.33
IUD 1 3.33
Pill 2 6.67
Pill & DMPA 3 10.00
None 17 56.67
Table 2. Characteristics of Biological Distribution Study Sample
Biological Characteristic Sample (n=30) Persentage
LVSI negative
(n=15)
LVSI negative
(n=15)
LVSI positive
(%=100)
LVSI positive
(%=100)
Clinical stage
IB 1 4 6 26.67 40
IB 2 6 6 40 40
II A 5 3 33.33 40
Histopathological diagnosis
Servical adenocarcinoma 3 6 20 40
Squamous cell carcinoma
Large cell non keratinizing type 12 7 80 46.67
Large cell keratinizing type 0 2 0 13.33
Differentiation degree
Well defined 1 3 6.67 20
Moderate 9 9 60 60
Poor defined 5 3 33.33 20
Table 3. Comparison Level of VEGF-C, Endostatin, and Ratio VEGF-C/ Endostatin
Variable LVSI p value
Positive (mean  SD) Negative (mean  SD)
Level of VEGF- C 12720.40  2593.13 10704.46  16909.86 0.17
Level of endostatin 178.20  33.99 170.46  31.24 0.552
Ratio VEGF- C/ endostatin 71.39  6.16 63.58  7.50 0.04
Vol 5, No 2
April 2017 Lympho vascular invasion in cervical cancer  107
DISCUSSION
In some other studies showed similar results that
cervical cancer frequently found at the age of 45-
55 years old, studies by Turah, Hasan and Perfitri.
In the United States, the mean age about 52.2 years.
Based on study by Aziz MF with gynecologic cancer
data in Indonesia on 2009, the peak age of cervical
cancer incidence is found in the age range 45-54
years old.
The results showed the sample is usually first
married at age  16 years old. One risk factor for
cervical carcinoma is sexual intercourse at an early
age. The result similar with study by MF Aziz that
suggested that the first sexual intercourse at age <
20 years old had higher risk of developing cervical
cancer than doing first sexual intercourse at the
age of > 20 years old.
Samples were generally educated middle and
high school as well as the daily activities as house-
wife. While the sample who graduated from college
were only two people. This result is accordance
with a study conducted by MF Aziz that showed
that were less educated had higher risk those who
were well educated and those who compared to
did not work have higher risk of developing cer-
vical cancer compared to those who work.
In terms of parity, frequency of marriage and
contraception usage showed that almost the entire
sample were multiparas and frequency of marriage
was once and samples generally did not use con-
traception. This is according to study by Aziz MF
which showed that multiparous women with the
number of children  6 have higher risk than
primiparous. In addition, it also concluded that
who were not taking birth control pills have higher
risk than those taking birth control pills.
In this study, the most histopathological type
samples were squamous cell carcinoma, large cell
non keratinize type. Based on study conducted by
AP Vizcaino, around two thirds of cervical cancer
types were squamous cell carcinoma and approxi-
mately 15% were adenocarcinoma.
The study showed that the level of VEGF-C
serum was higher in the LVSI positive (12720.40
 2593.13) than LVSI negative (10704.46 
1609.86) with p = 0.17. VEGF-C works well on
blood vessels and lymphatic vessels and play an
important role in the process of angiogenesis, and
metastasis limfangiogenesis. Study conducted by
Tjandra on 47 patients with early stage cervical
cancer found that stage results, the size of lesions
> 40 mm, degree of differentiation, limits of the
vaginal incision, limfo vascular invasion, levels of
VEGF-C > 10066.90 were lymph node metastasis
risk factor and they could be used as predictors.
Lesions size of > 40 mm, differentiation, para-
metrial invasion, levels of VEGF-C > 10066.90
were limfovascular invasion risk factor.
VEGF-C levels > 10066.90 is likely have 80
times risk get lymphnode metastasis com-
pared to VEGF-C  10066.90 (p < 0.001) and 12.5
times get limfo vascular invasion (p = 0.022).
Mitsuhashi A in his study concluded that the
levels of VEGF-C serum were signs of biomolecular
potential for cervical cancer squamous cell type.
Yu H did study in 2007-2009 in Qi Lu Hospital,
Shandong University on 97 patients with cervical
cancer stage Ia-IIa, which 30 of them had
positive lymphnode metastasis with the result of
VEGF-C, VEGF-D, FLT-4 relating to limfangio-
genesis. Similarly, in study by Wang et al on 89
patients (22 cervicitis chronic, 24 CIN, 43
squamous cell carcinomas) with a result higher
expression of VEGF-C in tissue, the higher levels in
serum (p = 0.024), VEGF-C in serum and tissues
associated with clinical stage, tumor size,
lymphnode metastasis and not related to the
degree of differentiation.
We could see that the levels of endostatin on the
LVSI positive (178.20  33.99) was higher than
LVSI negative (170.46  31.24), but this result
was not significant because the p-value was 0.552.
Tjandra found that endostatin levels  184.5 ng/ml
was a protection factor of the invasion limfo
vascular but in statistics are also not significant
(p = 0.562). Endostatin is an angiogenesis inhibitor.
It is produced by our body as a reaction of the
malignant tumor through the degradation of the
basement membrane. There were elevated levels
of endostatin in circulation (with over gene
expression in endothelial) less than 2 times can
suppress tumor growth by 2- 3 fold. It would
require further research on the relationship
endostatin with limfo vascular invasion with a
larger number of samples.
CONCLUSIONS AND SUGGESTIONS
Levels of VEGF-C and ratio VEGF-C/ endostatin are
higher in patients with early-stage cervical cancer
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with LVSI positive than negative. Further research
on angiogenesis inhibitor and endostatin in
cervical cancer with a larger number of samples
is required.
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